

Correction Notification: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act)

Correction of the announcement: Epigenomics AG increases share capital

Correction notification of the announcement of Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of October 28, 2013 - 9:00 pm CET

Epigenomics erroneously announced yesterday its intention to increase its share capital by up to EUR 4,136,720.00 from the authorized capital. Instead, Epigenomics plans to increase its share capital by up to EUR 828,504,00 by issuing new shares at EUR 4.993 per share, thus raising up to EUR 4,136,720.00 in total gross proceeds. The correct notification is:

Not for distribution in the United States

Berlin, Germany, October 28, 2013 - Epigenomics AG (ISIN: DE000A1K0516) announces that the Company's Executive Board today with the approval of the Supervisory Board has resolved on an increase of the Company's share capital by up to EUR 828,504 from the authorized capital, thus raising up to EUR 4.136.720 in total gross proceeds. This capital increase follows a previous capital increase, published via ad hoc announcement on October 27, 2013, through which the strategic partner BioChain invested into the Company. The newly issued shares resulting from the envisaged capital increase will be offered against contribution in cash in a private placement to institutional investors in Europe and the U.S.. The preemptive rights of the shareholders will be excluded. The issue price has been set at EUR 4.993 per share and equals the volume-weighted average XETRA trading price during the last three trading days including the day of this announcement.

The placement of the shares is scheduled for Tuesday, October 29, 2013. Following completion of the placement, the Supervisory and Executive Boards of the Company are going to resolve on the final amount of shares to be issued, such resolution to be disclosed by way of an ad hoc announcement without undue delay.

Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to build and strengthen the distribution capacities for its lead product Epi proColon®, a blood-based test for the detection of colorectal cancer.

-End of Ad hoc-

Disclaimer

This publication is not an offer of any securities for sale or a solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares of Epigenomics AG (the "Shares") have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the Shares in the United States and the Shares will not be registered under the Securities Act.

Contact:

Epigenomics AG

Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.